Abstract: Histopathologic diagnosis of cervical biopsies determines clinical management of patients with an abnormal cervical cancer-screening test yet is prone to poor interobserver reproducibility. Immunohistochemical staining for biomarkers related to the different stages of cervical carcinogenesis may provide objective standards to reduce diagnostic variability of cervical biopsy evaluations but systematic, rigorous evaluations of their potential clinical utility are lacking. To address diagnostic utility of human papillomavirus (HPV) L1, p16
, and Ki-67 immunohistochemical staining for improving diagnostic accuracy, we conducted a community-based and population-based evaluation using 1455 consecutive cervical biopsies submitted to the Department of Pathology at the University of Virginia during a period of 14 months. Thin-sections of each biopsy from 1451 of 1455 (99.7%) biopsies underwent evaluation of immunohistochemical stains for the 3 biomarkers, masked to the original diagnosis, and the results were compared with an adjudicated, consensus diagnosis by 3 pathologists. p16
INK4a immunostaining, using the strongest staining as the cutpoint, was 86.7% sensitive and 82.8% specific for cervical intraepithelial neoplasia (CIN) grade 2 or more severe (CIN2 + ) diagnoses. The performance of p16
INK4a was more sensitive (P<0.001), less specific (P<0.001), and of similar overall accuracy for CIN2 + compared with the combined performance of all pathologist reviews in routine clinical diagnostic service (sensitivity = 68.9%, specificity = 97.2%). Ki-67 immunostaining was also strongly associated with a CIN2 + diagnosis but its performance at all staining intensities was inferior to p16 INK4a immunostaining, and did not increase the accuracy of CIN2 + diagnosis when combined with p16
INK4a immunostaining compared with p16 INK4a immunostaining alone. We found no utility for L1 immunostaining in distinguishing between CIN and non-CIN. In conclusion, with a rigorous evaluation, we found immunohistochemical staining for p16 INK4a to be a useful and reliable diagnostic adjunct for distinguishing biopsies with and without CIN2 C ervical cancer prevention programs in the United States and other high-resource settings have traditionally relied on the repeated application of a 3-stage intervention: (1) screening by Pap tests/cervical cytology; (2) colposcopic evaluation (magnified visualization of the cervix after the application of dilute acetic acid) of screen positives and directed biopsy of abnormal-looking cervical tissue for diagnosis; and (3) excisional or ablative treatment of the cervical tissue in women diagnosed with precancerous lesions. This program of screening, diagnosis, and treatment of precancerous lesions has effectively reduced the burden and mortality owing to cervical cancer where it is has been effectively implemented. 1, 15 As most screen-positive women do not have clinically important disease, the goal of managing women who screen positive is distinguishing between those women who have precancerous lesions that have malignant potential and need treatment from those who have benign human papillomavirus (HPV)-associated lesions, which are most likely to regress spontaneously and can be monitored without immediate intervention. However, making such distinctions accurately (sensitively and specifically) has proven difficult.
In the United States, Canada, and some European countries, cervical histopathologic diagnoses are currently graded according to the cervical intraepithelial neoplasia (CIN) system: Normal, CIN1, CIN2, CIN3, and cervical cancer. The CIN nomenclature is primarily based on a subjective measure of the thickness, from the stroma toward the surface of the epithelium of the percentage replacement of differentiating epithelial cells by minimally differentiating or proliferating epithelial cells. At least two-thirds of the epithelium is replaced in CIN3, between one-third and two-thirds in CIN2, and one-third or less in CIN1. This classification system was developed before it was known that these intraepithelial lesions, while representing a spectrum of histologic changes caused by HPV, are actually 2 distinct and noncontinuous biologic processes, 1 benign and 1 precancerous. 29 In this context, CIN1 is the histopathologic manifestation of HPV infection by carcinogenic and noncarcinogenic HPV genotypes. CIN2 and CIN3 (sometimes called carcinoma in situ) are considered precancerous diagnoses. However, while CIN3 is considered a definite precancer and is the best surrogate for cancer risk, with 30% of CIN3 in older women becoming invasive over 30 years, 19 CIN2 is now considered an equivocal diagnosis of cervical precancer and includes both CIN1/HPV effects and some precancerous lesions. 5 The clinical challenge is to define which is which, that is which is of the equivocal diagnoses merits treatment as a precancer.
Histologic assessment of cervical dysplasia is complicated by interobserver variability equaling that of cytologic interpretion. 25 The 2 key interpretive issues include the distinction of normal from dysplasia (CIN) of any grade; and then benign, mostly transient dysplasia (CIN1) from precancer (CIN3 and some CIN2). The first issue, separating normal from any CIN, is most commonly the result of misclassifying a normal biopsy as CIN1. 25 Although this error might be viewed as trivial, an erroneous diagnosis of CIN1 provides false assurance to the colposcopist. Specifically if the diagnosis of CIN1 is rendered and indeed the histologic diagnosis is truly normal, the colposcopist thinks a lesion has been found when in fact normal epithelium has been biopsied and thus the ability to make accurate colposcopic and pathologic correlation is severely compromised. Furthermore, although not recommended by current management guidelines, 28 women diagnosed with CIN1 are sometimes aggressively treated.
Less often, truly precancerous or high-grade lesions are misclassified as negative for dysplasia particularly in the setting of reactive or metaplastic changes or when a biopsy is fragmented or poorly samples the underlying small lesion. Conversely, diagnostic errors resulting in the overcalling of negative as high-grade disease also occur. 6 Once dysplasia is recognized, the second diagnostic issue is to determine whether the lesion has malignant potential justifying a therapeutic excision, whereas attempting to minimize the overtreatment of lesions likely to regress. This is an important balance between safety and overtreatment because treatment increases the risk of negative reproductive outcomes for subsequent pregnancies. 2 Current protocols place this treatment threshold at CIN2, 28 but CIN2 has been shown to be the least reproducible diagnosis 4, 5, 25 and has much greater regressive potential than CIN3. 7, 26 In our view, although CIN2 is a heterogeneous cohort, 5 containing both precancerous and transient lesions, its treatment provides a necessary margin of safety against the risk of cancer.
We have earlier proposed a method for reducing interobserver variability in cervical biopsy interpretations, particularly CIN2, by using fractions attributable to HPV16 11 ; however, widespread genotyping is not yet available, and whereas applicable as a quality control metric for diagnostic tendencies, it is not helpful in the interpretation of any individual biopsy.
Other biomarkers have been proposed for use in triaging women with cervical dysplasia to increase diagnostic accuracy, akin to incorporating HPV testing into clinical practice as a triage of women with equivocal cytologic abnormalities to determine which women are in need of immediate colposcopy. 18, 23 Several candidate biomarkers, such as HPV L1, p16
INK4a
, Ki-67 and others, have been proposed for use on cytologic or histologic specimens based on promising preliminary results. 9, 13, 16, 17, 20, 30 To more rigorously evaluate the utility of HPV L1, p16
, and Ki-67 immunohistochemical staining for improving diagnostic accuracy, we conducted a community-based and population-based evaluation in almost 1500 consecutive cervical biopsies. Our goals reflected the diagnostic challenges described above: distinguishing dysplastic from normal tissue and delineating the grade of the lesion among women with dysplasia. This large study has assessed and minimized interobserver variation by conducting a centralized adjudicated review of histology. We also negated any auto-correction of stain interpretations by reviewing hematoxylin and eosin stain (H&E) slides for standard histologic diagnosis and grading the immunohistochemistry results in a masked fashion, thereby permitting an unbiased evaluation of each biomarker's independent contribution to the adjudicated histopathologic assessment.
METHODS

Cervical Biopsy Review and Data Collection
Routine clinical H&E-stained slides of all cervical biopsies accessioned for 14 consecutive months (n = 1455), excluding benign cervical polyps, were prospectively collected with documentation of the routine clinical diagnosis rendered by one of the on-service general anatomic pathologists (''clinical diagnosis''). The median age, mean age, and age range of this population was 26 years, 29 years, and 18 to 71 years, respectively. The use of the tissues for this study was approved by the institution review board of the University of Virginia, and the analysis of the deidentified data by P.E.C. was determined not to be human subjects research by the NIH Office of Human Subjects Research.
Slides underwent a quality control pathology review blinded to any clinical information except for patient age. A series of biopsies from a single patient were interpreted as separate biopsies. Diagnostic agreement between any 2 reviewing pathologists provided a ''consensus diagnosis.'' Slides first underwent independent reviews by 2 pathologists (M.H.S., K.A.A.). If there was diagnostic agreement between the first 2 reviewers, consensus diagnosis was achieved, and no additional reviews were conducted. For cases with diagnostic disagreement between the first 2 reviewers, an independent third review was conducted by another pathologist (M.T.G.). If there was diagnostic agreement on 2 of the 3 reviews, no additional reviews were done. Cases with 3-way independent disagreement were rereviewed together, masked to the earlier diagnoses, by 3 reviewing pathologists at a multiheaded microscope until a consensus diagnosis (2-way or 3-way agreement) was reached. This consensus was reached by H&E stains only; no immunohistochemical results were used.
All excisional follow-up diagnoses (hysterectomy, cold knife conization, or LEEP) were recorded. More certain diagnostic annotations, such as ''favor'' or ''consistent with,'' were considered informative (eg,: ''squamous dysplasia, favor moderate'' was coded as moderate squamous dysplasia). Less certain diagnostic annotations, such as ''cannot exclude,'' were not considered informative (eg, :''mild squamous atypia, cannot exclude mild squamous dysplasia'' was coded as negative). Biopsies documented as insufficient for diagnosis or diagnosed as benign cervical polyps were excluded from further review.
Results of the preceding Pap tests (the most proximate, available in-house Pap test within 3 years of the colposcopic examination) and Pap tests done at the time of colposcopy (''synchronous Pap test'') were tabulated when available. A subset of 1359 (93.7%) women had data on either a preceding Pap (n = 790, 54.4%) or a synchronous Pap (n = 980, 67.5%) (411, 28.3%, had both). Any accompanying HPV testing (Hybrid Capture 2; Qiagen, Gaithersburg, MD) was also recorded.
Histology and Immunohistochemistry
All colposcopically directed cervical biopsies were fixed in 0.25% zinc, neutral-buffered, 10% formalin (Richard-Allan Scientific, Kalamazoo, MI) and embedded in paraffin per routine. These were then cut at 4 mM for 10 sequential levels and placed on negatively charged, sialinated slides (Superfrost, Thermo Fisher Scientific, Inc., Waltham, MA). Slides 1, 2, and 10 were selected for hematoxylin and eosin staining and submitted to the onservice clinical faculty admixed with other routine noncervical surgical cases. Slides 3 to 9 were retained for additional analyses, including immunohistochemical staining.
For immunohistochemistry, unstained slides were placed in a 601C oven for 1 hour, cooled, deparaffinized, and rehydrated through xylenes and graded ethanol solutions to water. All slides were then treated for 5 minutes in a 3% hydrogen peroxide solution in water to quench endogenous peroxidase. Antigen retrieval for all immunohistochemistry was conducted using Target Retrieval Solution (Dako, Carpinteria, CA; product code S1699) in a pressure cooker per the manufacturer's protocol. Slides were then placed on a Dako Autostainer immunostaining system for use with immunohistochemistry. Nonspecific antibody binding was inhibited by incubating sections with serum-free protein block (Dako; product code X0909) for 10 minutes. Primary antibodies against p16
INK4a (mtm laboratories AG, Heidelberg, Germany; antibody used per package insert), Ki-67 (Dako; antibody diluted 1:300), and L1 capsid protein of all known HPV types (Cytoactiv Screening Set, Cytoimmun Diagnostics, Pirmasens, Germany; prediluted antibody) were applied for 1 hour at room temperature. After washing and incubation with the relevant secondary antibody linked to horseradish peroxidase, also for 1 hour at room temperature, sections were developed by adding DAB + (3,3 0 -Diaminobenzidine) chromogen (Dako; product code K3468) for 5 minutes. Slides were then counterstained in Richard-Allan hematoxylin, dehydrated through graded ethanol solutions, cleared with xylene, and cover-slipped.
Immunohistochemical Scoring
A fourth pathologist (W.K.B.) reviewed and scored all immunohistochemical stains in the epithelium of each biopsy without clinical information or corresponding H&E-stained slides. The scoring of p16 generally included both nuclear and cytoplasmic staining, and was graded as 0 (no staining), 1 (rare singly dispersed cells staining), 2 (patchy but strong staining, often not continuous from basement membrane), and 3 (strong and diffuse staining, usually continuous staining from basement membrane and extending upward in proportion to lesion grade). The scoring of Ki-67 included nuclear staining only, and was scored as 0 (no staining), 1 (1 to 2 layers of basal/parabasal staining), 2 (diffuse staining confined to the bottom third or superficial staining but with skip areas usually between parabasal and upper zones), and 3 (continuous staining of greater than the lower third of the epithelium). L1 was scored as positive if at least 1 epithelial cell had discrete nuclear staining. Figures 1-5 demonstrate examples of typical and problematic cases.
Statistical Analyses
A total of 1451 of 1455 (99.7%) individual cervical biopsies had both diagnoses and all immunohistochemical staining results. Histologic diagnoses were categorized as follows: Negative, CIN1, CIN2, CIN3/adenocarcinoma in situ (AIS), and cancer. We also categorized diagnoses as no CIN (negative) versus CIN [CIN1 or more severe (CIN1+)]. To examine the association of the biomarkers with the severity of CIN among women with any CIN, we grouped the small number of cancers with CIN3/AIS (CIN3/AIS/Cancer).
As measures of diagnostic agreement between the clinical and consensus diagnoses, we calculated the percent total (raw) agreement with binomial 95% confidence intervals (95% CI) and k values with 95% CI, and tested for a tendency for one or the other group to diagnose more severely using the symmetry w 2 test. Raw agreement, k values, and (if appropriate) linearly weighted k values were calculated for the subset of immunohistochemical stained slides read by a second reviewer (K.A.A.) to assess specifically the relative reproducibility of the adjunctive stains.
A Mantel-Haenzel test for trend was used to assess trends of staining positive or intensity with the severity of the consensus diagnosis. Sensitivity, specificity, and Youden's Index (YI) (YI = sensitivity+specificity-1), as a metric of accuracy, were calculated for consensus diagnoses of CIN3 and more severe (CIN3 + ), CIN2 + , and CIN1 + . McNemar w 2 was used to test for differences in sensitivity and specificity.
Logistic regression was used to calculate odds ratios (OR) with 95% CI for the association of biomarker immunohistochemical staining with having CIN versus having no CIN, and multinomial logistic regression was used to calculate OR with 95% CI for the association of biomarker immunohistochemical staining with the severity of diagnosis among women with any CIN (CIN3 or CIN2 vs. CIN1).
Two-sided Fisher exact tests were used to examine discrepancies in consensus diagnosis and p16
INK4a immunohistochemical staining intensity (eg, <CIN2 and score of 3).
P values of less than 0.05 were considered statistically significant. Stata 8 (College Station, TX) was used for statistical analyses.
RESULTS
The pair-wise clinical and consensus diagnoses are shown in Table 1 . As rendered by academic surgical pathologists in routine general sign-out, there were 755 negative (52.0%), 451 CIN1 (31.1%), 147 CIN2 (10.1%), 92 CIN3/AIS (6.3%), and 6 cancer (0.4%) diagnoses. The consensus panel review of these biopsies resulted in 748 negative (51.6%), 394 CIN1 (27.2%), 177 CIN2 (12.2%), 127 CIN3/AIS (8.8%), and 5 cancer (0.3%) diagnoses. Raw agreement between the clinical diagnosis and consensus diagnosis was 74.2% (95% = 71.8-76.4%) and the k value was 0.59 (95% CI = 0.55-0.62). There was a 76.8% agreement for negative histology, 49.3% for CIN1, 27.6% for CIN2, 46.0% for CIN3, 83.3% for cancer diagnoses. The consensus review had a tendency to render a more severe diagnosis than the clinical diagnosis (P<0.001); notably the consensus review was more likely to call the clinical diagnosis of CIN2 as CIN3/AIS than the converse (48 vs. 20) and to call a community diagnosis of CIN1 as CIN2 than the converse (77 vs. 23).
Immunohistochemical staining results for HPV L1, p16 INK4a , and Ki-67 were associated/related to each other.
Increasing intensity of p16
INK4a and Ki-67 immunohistochemical staining were strongly and directly correlated (p trend <0.001), whereas HPV L1 positivity decreased with increasing intensity of p16
INK4a (p trend <0.001) and Ki-67 (p trend <0.001).
Shown in Table 2 are the results of the individual immunohistochemical stains versus the consensus diagnosis. Increasing intensity of p16
INK4a (p trend <0.001) and Ki-67 (p trend <0.001) immunohistochemical staining was associated with the increasing severity of the consensus diagnosis. Statistically, immunohistochemical staining of HPV L1 (p trend <0.001) was negatively associated with the increasing severity of the consensus diagnosis. As would be predicted by the natural history of HPV and cervical carcinogenesis, negative histology (96.7%) and cancer (100%) were the most likely to test negative for L1 capsid protein.
We next examined the clinical performance (sensitivity, specificity, and YI) of different positive cutpoints for p16
INK4a and Ki-67 staining, and the 2 markers combined, in relationship to the consensus diagnoses of CIN3 + , CIN2 + , and CIN1 + (Table 3) . Increasing the positive cutpoint for p16
INK4a staining increased its specificity and accuracy for CIN3 + and CIN2 + with only a minor decrement in sensitivity owing to one case of CIN3/AIS having a staining intensity of 1 (discussed below). By comparison, increasing the positive cutpoint for Ki-67 staining increased its specificity and accuracy for CIN3 + and CIN2 + but there was a greater decrement in sensitivity. Combining the staining results for 2 biomarkers in general did little to enhance the clinical performance for CIN3 + compared with p16 INK4a staining alone: the most accurate combination of p16
INK4a
(cutpoint = 3) and Ki-67 (cutpoint = 2) was only slightly less sensitive (98.5% vs. 99.2%), more specific (78.1% vs. 74.8%), and had a higher YI (76.6% vs. 74.0%) than p16
INK4a (cutpoint = 3) staining alone. We used logistic regression models to examine the association of each biomarker with having CIN (versus FIGURE 4. Consensus rCIN1 on H&E (A), with strong 3+ p16 staining (B). On retrospective review, the focus interpreted as inflamed squamous metaplasia was reconsidered by all reviewers to be missed CIN3 even although the excisional specimen (LEEP) was negative for dysplasia. Consensus rCIN1 on H&E (C) with strong 3+p16 staining (D). On retrospective review, the small freefloating focus has unknown significance, and no excisional specimen was submitted. Magnification on the film plane = 6 Â in A and B and 15 Â in C and D.
not) and the severity of CIN among those with any CIN (with CIN1 being the reference), mutually adjusting for the other biomarkers. In the models, we used a positive cutpoint of 3 for p16 INK4a and Ki-67 staining. HPV L1 (OR = 8.1, 95% CI = 5.1-13.1), p16
INK4a (OR = 16, 95% CI = 11-23), and Ki-67 (OR = 18, 95% CI = 4.3-77) staining were associated with having CIN. p16
(OR = 4.7, 95% CI = 3.1-7.3) and Ki-67 (OR = 5.4, 95% CI = 2.9-9.9) staining were associated, and HPV L1 (OR = 0.62, 95% CI = 0.40-0.95) was negatively associated with, having a CIN2 + diagnosis. p16
(OR = 140, 95% CI = 18-1000) and Ki-67 (OR = 22, 95% CI = 11-42) staining were associated, and HPV L1 (OR = 0.18, 95% CI = 0.098-0.35) was negatively associated with having a CIN3+diagnosis. Among women with a negative or CIN1 consensus diagnosis, women whose biopsy had p16
INK4a immunohistochemical staining score of 3 (see examples in Fig. 4 ) compared with those who had a score of <3 were: (1) more likely to have community diagnosis of CIN1+ (69.6% vs. 25.9%; P<0.001) and CIN2 + (9.7% vs. 1.4%, P<0.001) and (2) more likely to have a preceding or synchronous HSIL Pap (24.6% vs. 16.3%; P<0.001). Among women with a CIN2 consensus diagnosis, The shadowed cells highlight exact agreement between the 2 diagnoses. Raw agreement between the clinical diagnosis and consensus diagnosis was 74.2% (95% CI = 71.8-76.4%) and the k value was 0.59 (95% CI = 0.55-0.62).
AIS indicates adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia.
women whose biopsy had p16 INK4a immunohistochemical staining score of 3 compared with those who had a score of <3 were: (1) more likely to have community diagnosis of CIN1 + (98.5% vs. 80.0%; P<0.001) and CIN2 + (54.0% vs. 40.0%, P = 0.2); (2) more likely to have a preceding or synchronous HSIL Pap (86.2% vs. 68.0%; P = 0.005); and (3) more likely to have a diagnosis of CIN2 + on their excised tissue (89.3% vs. 70.3%, P = 0.03). The one case of a CIN3 consensus diagnosis with immunohistochemical staining score less than 3 also had a CIN3 clinical diagnosis, a preceding Pap of atypical squamous cells, was positive for HPV L1, and Ki-67 immunohistochemical staining score of 2 (Fig. 5) . The subsequent excision was diagnosed as CIN3. This most likely represents a rare technical failure of the p16 immunostain. Table 4 compares the sensitivity, specificity, and Youden's Index of p16
INK4a with or without Ki-67 immunostaining with individual pathologists' H&E interpretations INK4a with or without Ki-67 immunostaining was an equally sensitive but slightly less specific and less accurate (lower YI) diagnostic method compared with the combined performance of all pathologist reviews (using a diagnostic cutpoint of CIN2 or worse) (Sensitivity, P = 0.01; Specificity, P<0.001) and to most of the individual performances of each pathologist singly. Similarly for an endpoint of CIN2 + , p16
INK4a with or without Ki-67 immunostaining was more sensitive but less specific diagnostic method compared with the combined performance of all pathologist reviews (Sensitivity, P<0.001; Specificity, P<0.001) and to most of the individual performances of each pathologist singly. Ranked according to YI, p16 INK4a with or without Ki-67 immunostaining was near the middle of diagnostic accuracy for CIN2 + for the 12 surgical pathologists.
A random subset of immunohistochemical stained slides underwent a second review to assess the reproducibility of grading of the immunochemical stain. The raw agreement and k for HPV L1 immunostaining (n = 159) were 96.9% and 0.88, respectively. The raw agreement, k, and linear-weighted k for Ki-67 immunostaining (n = 162) were 73.6%, 0.55, and 0.67, respectively. The raw agreement, k, and linear-weighted k for p16 INK4a immunostaining (n = 162) were 76.5%, 0.64, and 0.80, respectively. Using the p16
INK4a immunohistochemical staining score of 3 as the positive cutpoint, the raw agreement was 95.1% and k was 0.87. Using the p16 INK4a immunostaining score of 3 and a Ki-67 immunostaining of 2 + as the positive cutpoint, the raw agreement was 95.0% and k was 0.86. By comparison, the ranges in the raw agreements and k values between the 3 pathologists conducting the consensus reviews were 88.3% to 91.9% and 0.67 to 0.72, respectively.
DISCUSSION
There is little doubt that the pathology community agrees on the utility of adjunctive stains to increase the accuracy of clinical histologic interpretations. Many studies 9, 12, 13, 16, 17, 20, 30 have provided evidence that Ki-67 and p16
INK4a immunohistochemistry are valuable adjunctive aids in the diagnosis of difficult cervical biopsies. However, virtually none of these studies take into account the realities of diagnostic variation and the confounding effect of autocorrelation. Furthermore interpretation of immunohistochemistry can also be subjective and there are no criteria that are widely accepted for what the exact cutpoint for a positive versus negative immunohistochemical stain should be. Mix all these variables together and it becomes difficult to be able to get any accurate assessment of a biomarker's performance for its stated purpose.
Patient management is highly contingent on histopathologic diagnosis. Although widely used in clinical studies as the determinative endpoint for clinical trials, adjudicated histology is not the standard of care. Furthermore biomarker studies such as the immunochemical stains evaluated in this article are used adjunctively at the discretion of pathologists. Indeed, part of the decision of whether to apply a special stain or not to a given case is completely dependent on whether the pathologist thinks they have a problem. Given the documented interobserver variation of histologic diagnosis, together with the fact that these studies have documented that the biggest error in interpretations are at the thresholds of CIN versus non-CIN and even more critically CIN1 versus CIN2 + , one could legitimately ask the questions as to whether biomarkers could be used to override or replace H&E diagnosis. To accomplish this goal, a clear index of performance of each potential marker, alone or in combination, must be established relative to an accepted diagnostic gold standard. This study was designed to address all these issues and the limitations with the existing literature.
We documented again the diagnostic variation in histologic diagnosis as has been observed earlier. 4, 5, 25 Although findings in this intradepartmental study, given its relative tendency to under-call CIN2, are slightly different than ALTS, 5,25 the overall impression of diagnostic variation and trends are still markedly evident. This was all true despite the fact that many of the faculty have worked together continuously for more than a decade to harmonize diagnoses in order to achieve more consistent management of patients. Indeed, these data from an optimal yet real-world setting highlight the difficulty in achieving reliable diagnostic performance without objective standards, and the circularity of the problem of evaluating biomarkers to address this issue in the absence of a clear gold standard. In other words, Se indicates sensitivity; Sp, specificity; YI, Youden's Index (Sp+Se À 100%).
